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small organizations (84.0%, n3,243,961). Regression analyses indicated that in-
creased expenditures were associated with large organizations (exp(b)2.00,
p0.025) andprostate cancer (exp(b)1.88, p0.039). Increased disability dayswere
associated with melanoma (exp(b)3.57, p0.039) and cancer of the uterus
(exp(b)4.90, p0.006). Higher resource utilization was associated with breast can-
cer (exp(b)1.76, p0.011) and cancer of the uterus (exp(b)1.85, p0.025).
CONCLUSIONS:Cancer is associatedwith a substantial burden in theworkplace, as
3.86 million persons were diagnosed with new cases or had continued treatment
while being employed in large or small organizations in 2007. Healthcare expendi-
tures summed to $59.3 billion, while 35.8 million total disability days were in-
curred.
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OBJECTIVES: Acute lymphocytic leukemia (ALL) is most common in children. Due
to advances in therapy options, the number of long term survivors of pediatric ALL
continues to increase. However, although prognosis has improved significantly
over time, ALL likely continues to impose a significant economic burden on society.
This study sought to assess recent trends in pediatric ALL hospitalization and
aspects of related care. METHODS: Data for pediatric (20 years) hospitalizations
with a primary diagnosis of ALL (ICD-9-CM codes 204.0x) from the 1997, 2000, 2003,
and 2006 HCUP Kids’ Inpatient Databases were analyzed. Weighted estimates of
the number of hospitalizations for ALL and associated resource-based outcomes
(i.e., total charges, length of stay [LOS], and stem cell transplant procedures) were
derived. RESULTS: Between 1997 and 2006, the rate of pediatric ALL-related hospi-
talizations (per 100,000 2010 US pediatric population) increased slightly then lev-
eled off, from 6.10/100,000 in 1997 to 6.61/100,000 in 2000, 6.60/100,000 in 2003, and
6.62/100,000 in 2006. Mean LOS remained consistent until an increase in 2006 (12.1
days in 1997, 12.4 days in 2000 and 2003, to 13.6 days in 2006). Similarly, the pro-
portion of ALL hospitalizations with evidence of stem cell transplant remained
roughly unchanged at 60% until a sharp increase in 2006 to 64.9%. Finally, mean
costs (2010 USD) for ALL-related stays have increased nearly 31%, from $43,247
(1997) to $56,517 (2006). CONCLUSIONS: We examined rates of pediatric ALL-re-
lated hospitalizations and documented aspects of inpatient ALL care, and observed
a slight increase in the rate of hospitalizations over time. An increase in LOS was
seen in 2006, with a commensurate increase in total costs, possibly owing to a
marked increase in the rate of stem cell transplant. These findings may be used to
support access strategies (e.g., economic modeling efforts) for current ALL thera-
pies, as well as for those in the developmental stage.
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OBJECTIVES: To assess the average total daily CINV-related hospital outpatient
visit cost (CINV-OC) among patients with cancer treated with any chemotherapy
(CT) and initiated on anti-emetic prophylaxiswith palonosetron versus other 5-HT3
receptor antagonists (5-HT3 RAs) in a hospital outpatient setting. METHODS: Pa-
tients with a cancer diagnosis initiating CT and palonosetron (Group 1) and other
5-HT3-RAs (Group 2) for the first time (index date) between April 1, 2007-March 31,
2009 were identified from the Premier Perspective database. Key inclusion criteria
were patients aged  18 years and no nausea and/or vomiting and CT and anti-
emetic medication use in the 6-month pre-index date period. A multivariate GLM
model estimating the average daily CINV-OC in the follow up period (first of eight
CT cycles or sixmonths post-index date) was developed after adjusting for baseline
differences in several demographic and clinical variables. RESULTS: Of 9,144 iden-
tified patients, 1,775 (19.4%) initiated palonosetron. Versus group 2 patients, group
1 patients were significantly younger [61.2 (SD: 13.0) vs. 62.8 (13.1) years; p0.0001],
comprised more females [52.5% vs. 41.1%; p0.0001], less African American pa-
tients [8.6% vs. 13.2%; p0.0001] and more Hispanic patients [6.0% vs. 4.1%;
p0.0001], and a lower percent of patients received LEC and MinEC combined
(14.3% vs. 31.8%; p0.0001). In the follow-up period, unadjusted average daily
CINV-OC among group 1 patients was significantly lower versus group 2 patients
[$1,047.9 (SD: $1,444.5) vs. $1,339.1 (SD: $2,040.0); p0.0014]. After controlling for
potential confounders, the regression model predicted a 12.0% decrease in the
average CINV-OC; p0.0076 in favor of group 1 patients versus group 2 patients.
CONCLUSIONS: In this retrospective hospital outpatient study, patients with can-
cer treated with CT and initiated on palonosetron anti-emetic prophylaxis were
more likely to experience a significantly lower average daily CINV-OC versus those
initiated with other 5-HT3-RAs.
PCN49
THE RELATIONSHIP OF AGE AND SEX WITH COST OF TREATMENT FOR
CHRONIC LYMPHOCYTIC LEUKEMIA IN UKRAINE
Mandrik O, Zalis’ka O
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
OBJECTIVES: The major aims of the current research are to learn the average cost
of treatment of Chronic lymphocytic leukemia (CLL) in Ukraine and examine fac-
tors that may be associated with it. The number of patients burdened by the dis-
ease in Ukraine is considerable and cost implications for individuals requiring care
are significant. In Ukraine only limited amounts of necessary medicines are com-
pensated by the government, with the major expenses covered by patients
themselves. METHODS: A database containing records from hospital cards (2004-
2010) for patients with CLL was analyzed retrospectively. The sample was com-
posed of 113 patients, aged 39 to 85 (mean age 61.3, 61.9% males). Medicine costs
related only to direct diagnosis were calculated. RESULTS: The average annual
costs of pharmaceutical treatment for patient with relapse were $1,561.16 (1$7.95
UAH on 12.01.2011). A negative correlation was found to exist between age of the
patient’s diagnosis and costs of treatment (r.218; p .05). Furthermore, similar
to past research in other countries male gender was associated with a significant
increase in treatment costs, t(109)1.95, p.05. CONCLUSIONS: Although other
studies on CLL have shown a positive association between treatment cost and age,
our research showed an opposite association for the sample studied in Ukraine. A
possible explanation can be income limitations among the elderly thatmay restrict
their ability to pay for medicines and, simultaneously, cause doctors to prescribe
lower-priced pharmaceuticals. The average annual cost of treatment for CLL is
higher than the minimum subsistence level, equal to $1,320.75 for people of work-
ing age and $1,107.92 for the retired population. To ensure effective treatment,
especially for vulnerable populations, reimbursement for pharmaceuticals should
be implemented.
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OBJECTIVES: In Hungary, costs of anti-cancer protocols are covered by hospitals’
budget, and the funds of therapy expenditures provided by DRG accounts, on
a”cycle-by cycle” basis. Main goal of research was to investigate the cost of medi-
cines of colon cancer chemotherapies and compare to DRG based remittance allo-
cated by National Health Fund. METHODS: Cost analysis of CRC chemotherapy
protocols has been conducted from the perspective of audited Oncology Centres.
Regimens of 5-fluorouracil, raltitrexed, capecitabine, irinotecan, cetuximab, bev-
acizumab and oxaliplatin have been investigated, focusing on cost of medication,
and DRG value of protocols. Research time horizon was January-June 2010.
RESULTS: Real expenditures of protocols were assessed. The range of drug related
costs were 3.1-3412.9 USD as expenditures of hospitals. Total expenditures of che-
motherapy-regimens have been assessed and compared to allocation of remit-
tances from National Health Fund Administration. The value of remittances have
been found between 303.7 and 3261.8 USD, depending on protocols. The analysis of
drug expenditures and remittances has resulted a wide range of gap:- 178.0 to
1167.5 USD. The ratio of drug related expenditures and total remittance of hospitals
showed diversity from 1.0% to 125.1%. CONCLUSIONS: As demonstrated by the
analysis of costs, one of the reasons of the increase in expenditures spent on the
therapy of metastatic colon cancer is the emerging of these new, expensive high effi-
ciency therapies. Analysis showes, that fixed DRG values does not represent expendi-
ture of chemotherapies of CRC treatment. Neihter priority, nor incentive elements
have been found in protocols, containing molecules with high efficacy or improved
safety. Remittances should be validated regulary, based on hospitals’ perspective.
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OBJECTIVES: Consultation planning (CP), a decision support service for patients
provided by trained lay people, increases cancer patient’s decision-self-efficacy
(DSE) when conducted in-person. It may be more cost-beneficial to conduct CP by
telephone. Compare DSE, costs, willingness-to-pay (WTP) and cost-benefit (CBA) of
two CP delivery methods in rural breast cancer patients. METHODS: Randomly
assigned clients from cancer resource centers were enrolled (n67). Interventions
were CP in-person (n32) or by telephone (n35) between patients and trained
resource center staff to discuss knowledge for informed care decisions at their next
physician visit. Outcomeswere DSE andWTP for services. 2009 costs of training, CP
and patient time, travel, telephone, and center overhead were determined. We
compared costs and WTP using t-tests, ranked-sum or Kolmogorov-Smirnov tests
depending on Shapiro-Wilk tests for normality. CBA compared net benefit and CB
ratios for deliverymethods. RESULTS:As hypothesized, DSE did not differ between
deliverymethods (mean3.44 in-person;3.54 telephone) but each improved signif-
icantly (p0.001). Patients’ WTP did not differ by method; telephone ($154), in-
person ($144) (p0.78). Intervention costs were significantly lower for telephone
than in-person ($139 vs $181,p0.001) due to higher patient travel for in-person
($26 vs $2,p0.001). Training costs were $5.78-$147/person depending on amorti-
zation volume. Net benefit for telephone over in-person is $52; $42 less cost, with
$10 more value. CB ratios when training ($6.00-$147/patient) and overhead ($25/
patient) are added to program costs are 0.41-0.68 for in-person and 0.49-0.90 for
telephone depending on number delivered, so patients are WTP up to 68% of in-
person and 90% of telephone costs; 22% more return-on-investment for telephone
CP. CONCLUSIONS: Telephone delivery is more cost-beneficial than in-person CP.
The value of CP is the same for eithermethod and there are significant cost savings
with telephone delivery. Adoption of CP by telephone could result in additional
access for rural patients.
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